The complex role of angiopoietin-2 in the angiopoietin-Tie signaling pathway

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 9, 2012, Pages

  Thurston, Gavin ^a   Daly, Christopher ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANGIOPOIETIN RECEPTOR BLOCKER; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE VE PTP; TIE 1 RECEPTOR; TIE RECEPTOR; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; LIGAND; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; ARTICLE; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; ENDOTHELIUM CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASCULITIS;

ANGIOPOIETIN-2; ANIMALS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; LIGANDS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TIE-1; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULITIS;

EID: 84875807200     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006650     Document Type: Article

References (71)

1. Augustin HG, Koh GY, Thurston G, Alitalo K. 2009. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
2. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM. 2004. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94: 984-992.
3. Baumer S, Keller L, Holtmann A, Funke R, August B, Gamp A, Wolburg H, Wolburg-Buchholz K, Deutsch U, Vestweber D. 2006. Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 107: 4754-4762.
4. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp GL, Zhang X, Matthay MA, Ware LB, Homer RJ, et al. 2006. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 12: 1286-1293.
5. Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. 2000. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 156: 2179-2183.
6. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, et al. 2010. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156.
7. Chen L, Yang Z, Wang G, Wang C. 2001. Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma. J Tongji Med Univ 21: 228-235.
8. Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH, Yasunaga K, KimKT, Kim I, Choi HH, et al. 2004. COMP-Ang 1: A designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci 101: 5547-5552.
9. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, et al. 2010. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: Implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9: 2641-2651.
10. Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, Lai KM, Lin HC, Ioffe E, Yancopoulos GD, et al. 2004. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18: 1060-1071.
11. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, Griffiths J, Ioffe E, DalyTJ, Fandl JP, Papadopoulos N, et al. 2006. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci 103: 15491-15496.
12. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, BrunoJ, Radziejewski C, Maisonpierre PC, et al. 1996. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
13. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, XuA, Leidich R, Radziejewska E, Rafique A, et al. 2003. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10: 38-44.
14. Davis JS, Yeo TW, Piera KA, Woodberry T, Celermajer DS, Stephens DP, AnsteyNM. 2010. Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity. Crit Care 14: R89. doi: 10. 1186/cc9020.
15. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A. 2010. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 16: 420-429.
16. Dominguez MG, Hughes VC, Pan L, Simmons M, Daly C, Anderson K, Noguera-Troise I, Murphy AJ, Valenzuela DM, Davis S, et al. 2007. Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci 104: 3243-3248.
17. Duda DG, Batchelor TT, Willett CG, Jain RK. 2007. VEGF-targeted cancer therapy strategies: Current progress, hurdles and future prospects. Trends Mol Med 13: 223-230.
18. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML. 1994. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897-1909.
19. Durkin AJ, Bloomston M, Yeatman TJ, Gilbert-Barness E, Cojita D, RosemurgyAS, Zervos EE. 2004. Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumors. J Am Coll Surg 199: 724-731.
20. Emoto M, Charnock-Jones DS, Licence DR, Ishiguro M, Kawai M, Yanaihara A, Saito T, Hachisuga T, Iwasaki H, Kawarabayashi T, et al. 2004. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma. Gynecol Oncol 95: 474-482.
21. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, OlinerJD, McDonald DM. 2009. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
22. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG. 2004. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
23. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, et al. 2006. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 12: 235-239.
24. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. 2008. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 10: 513-526.
25. Fuxe J, Lashnits E, O'Brien S, Baluk P, Tabruyn SP, Kuhnert F, Kuo C, ThurstonG, McDonald DM. 2010. Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation. Am J Pathol 176: 2009-2018.
26. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, WitteC, Witte MH, Jackson D, et al. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423.
27. Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA. 2000. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87: 603-607.
28. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, et al. 2010. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103: 1407-1414.
29. Hanahan D. 1997. Signaling vascular morphogenesis and maintenance. Science 277: 48-50.
30. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, OlinerJD, McDonald DM. 2010. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70: 2213-2223.
31. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, AugustinHG. 2009. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15: 1384-1392.
32. Holash J, Wiegand SJ, Yancopoulos GD. 1999. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18: 5356-5362.
33. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, et al. 2010. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17: 1001-1011.
34. Jho D, Mehta D, Ahmmed G, Gao XP, Tiruppathi C, Broman M, Malik AB. 2005. Angiopoietin-1 opposes VEGF-induced increase in endothelial permeability by inhibiting TRPC1-dependent Ca2 influx. Circ Res 96: 1282-1290.
35. Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, et al. 2002. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160: 1683-1693.
36. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. 2000a. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ Res 86: 24-29.
37. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY. 2000b. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552.
38. Kim I, Kim JH, Ryu YS, Liu M, Koh GY. 2000c. Tumor necrosis factor-α upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun 269: 361-365.
39. Kim I, Moon SO, Park SK, Chae SW, Koh GY. 2001. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89: 477-479.
40. Li JJ, Huang YQ, Basch R, Karpatkin S. 2001. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85: 204-206.
41. Li X, Hahn CN, Parsons M, Drew J, Vadas MA, Gamble JR. 2004. Role of protein kinase Cς in thrombin-induced endothelial permeability changes: Inhibition by angiopoietin-1. Blood 104: 1716-1724.
42. Li Z, Huang H, Boland P, Dominguez MG, Burfeind P, Lai KM, Lin HC, Gale NW, Daly C, Auerbach W, et al. 2009. Embryonic stem cell tumor model reveals role of vascular endothelial receptor tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis. Proc Natl Acad Sci 106: 22399-22404.
43. Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M. 2009. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 41: 118-124.
44. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, YancopoulosGD, Channon KM, Hale LP, Dewhirst MW, George SE, et al. 1998. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci 95: 8829-8834.
45. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
46. Mandriota SJ, Pepper MS. 1998. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83: 852-859.
47. Moon WS, Park HS, Yu KH, Jang KY, Kang MJ, Park H, Tarnawski AS. 2006. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci 21: 272-278.
48. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG. 2009. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
49. Nykanen AI, Pajusola K, Krebs R, Keranen MA, Raisky O, Koskinen PK, Alitalo K, Lemstrom KB. 2006. Common protective and diverse smooth muscle cell effects of AAV-mediated angiopoietin-1 and-2 expression in rat cardiac allograft vasculopathy. Circ Res 98: 1373-1380.
50. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. 2004. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516.
51. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. 1995. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14: 5884-5891.
52. Saharinen P, Kerkela K, Ekman N, Marron M, Brindle N, Lee GM, Augustin H, Koh GY, Alitalo K. 2005. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 169: 239-243.
53. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, et al. 2008. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10: 527-537.
54. Sato TN, Qin Y, Kozak CA, Audus KL. 1993. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci 90: 9355-9358.
55. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. 1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
56. Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu M, Wiedenmann B, Berg T, et al. 2007. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 102: 2471-2481.
57. Stratmann A, Risau W, Plate KH. 1998. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153: 1459-1466.
58. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
59. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD. 1998. Increased vascularization in mice overexpressing angiopoietin-1. Science 282: 468-471.
60. Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM. 2010. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am J Pathol 177: 3233-3243.
61. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ. 2001. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670.
62. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonaldDM. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514.
63. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463.
64. Thurston G, Wang Q, Baffert F, Rudge J, Papadopoulos N, Jean-Guillaume D, Wiegand S, Yancopoulos GD, McDonald DM. 2005. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132: 3317-3326.
65. van der Heijden M, van Nieuw Amerongen GP, Chedamni S, van Hinsbergh VW, Johan Groeneveld AB. 2009. The angiopoietin-Tie2 system as a therapeutic target in sepsis and acute lung injury. Expert Opin Ther Targets 13: 39-53.
66. Vikkula M, Boon LM, Carraway KL III., Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, et al. 1996. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87: 1181-1190.
67. Winderlich M, Keller L, Cagna G, Broermann A, Kamenyeva O, Kiefer F, DeutschU, Nottebaum AF, Vestweber D. 2009. VE-PTP controls blood vessel development by balancing Tie-2 activity. J Cell Biol 185: 657-671.
68. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. 2005. Protective role of angiopoietin-1 in endotoxic shock. Circulation 111: 97-105.
69. Xu Y, Yu Q. 2001. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 276: 34990-34998.
70. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, WoolfAS, Karumanchi SA. 2007. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J 21: 3171-3183.
71. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos GD, Grumet M. 1999. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159: 391-400.